Patents by Inventor C. Valerie

C. Valerie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genetic inhibition of epidermal growth factor receptor function and carcinoma cell radiosensitization
    Publication number: 20050239738
    Abstract: The present invention is drawn to a method of suppressing the phenomenon of accelerated repopulation, i.e. the proliferation of cells upon exposure to a clinically relevant dose of radiation energy. More specifically, the invention provides a method of radiosensitizing cancer cells by administering an expressible nucleic acid molecule encoding a mutant form of epidermal growth factor receptor. In a preferred embodiment of the invention, the mutant form of epidermal growth factor receptor is EGFR-CD533, a C-terminal truncated epidermal growth factor receptor that lacks mitogenic and transformation activity. The method of this invention thus constitutes a gene therapy approach to the radiosensitization of cancer cells.
    Type: Application
    Filed: June 8, 2005
    Publication date: October 27, 2005
    Inventors: Rupert Schmidt-Ullrich, C. Valerie
  • Tumor radiosensitization with mutant thymidine kinase in combination with a prodrug
    Publication number: 20010046491
    Abstract: The present invention provides a method for radiosensitizing cancer cells and tumors by utilizing a high activity form of thymidine kinase (TK) and a prodrug. The inventions also provides a method for killing cancer cells and for treating cancerous tumors in a mammal by utilizing a high activity form of thymidine kinase and a prodrug, in combination with radiation. In preferred embodiments, the high activity form of TK is a mutant of herpes simplex virus (HSV) TK and the prodrug is acyclovir.
    Type: Application
    Filed: March 23, 2001
    Publication date: November 29, 2001
    Inventor: Kristoffer C. Valerie